002099 海翔藥業
按盤價 
5.410 +0.060 (+1.121%)
5.410 +0.060 (+1.121%) | 2026/03 - 三個月 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 486,497 | 0.01% | 1,860,694 | 1,938,466 | 2,171,887 | 2,704,144 | |
| 減：營業總成本 | 494,767 | 6.02% | 1,897,235 | 1,859,241 | 2,333,342 | 2,476,305 | |
| 其中:營業成本 | 354,451 | -2.66% | 1,405,934 | 1,420,156 | 1,867,244 | 1,983,870 | |
| 財務費用 | 21,758 | -343.27% | 4,247 | (60,065) | (31,317) | (102,478) | |
| 資產減值損失 | (35,415) | 206.13% | (102,558) | (425,167) | (237,861) | (83,768) | |
| 公允價值變動收益 | 1,131 | -62.94% | (14,791) | (16,490) | (104,254) | (19,584) | |
| 投資收益 | 65,925 | 3,470.30% | 55,647 | 8,783 | (13,370) | (22,752) | |
| 其中：對聯營企業和合營企業的投資收益 | 54,972 | -5,017.81% | 33,749 | (11,187) | (16,844) | (32,971) | |
| 營業利潤 | 25,459 | 59.14% | (80,026) | (336,143) | (464,243) | 109,399 | |
| 利潤總額 | 26,113 | 107.27% | (84,091) | (336,881) | (466,223) | 100,803 | |
| 減：所得稅費用 | (189) | -104.42% | 9,663 | (2,994) | (44,642) | 14,725 | |
| 淨利潤 | 26,303 | 216.39% | (93,754) | (333,887) | (421,581) | 86,078 | |
| 減：非控股權益 | (144) | -84.33% | (2,679) | (3,620) | (1,525) | (1,936) | |
| 股東淨利潤 | 26,446 | 186.53% | (91,076) | (330,267) | (420,056) | 88,014 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.020 | 100.00% | -0.060 | -0.210 | -0.260 | 0.050 | |
| 每股派息 (元) * | -- | -- | -- | -- | -- | 0.050 | |
| 每股淨資產 (元) * | 3.052 | -4.03% | 3.113 | 3.175 | 3.463 | 3.773 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 28/05/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
